The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from ...

The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on ...

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...

HHS Secretary Robert F. Kennedy Jr named 8 new members to the CDC’s Advisory Committee on Immunization Practices.

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

aNational Institute for Health and Care Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, UK bFaculty of Medicine ...

ucl.ac.uk Respiratory syncytial virus (RSV) is the most common single cause of respiratory hospitalisation of infants and is the second largest cause of lower respiratory infection mortality worldwide ...

Nasopharyngeal swabs were collected from children 0–2 years of age with ILI and tested for influenza, respiratory syncytial virus (RSV), and SARS-CoV-2 ... This study involves human participants and ...